Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA (NCT07780968)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to collect real-world data to describe the effectiveness and tolerability of first line (1L) zanidatamab-containing therapies and describe the subsequent lines of treatment in participants with unresectable, locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA) (HER2+ la/m GEA).
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (5 items).
Location: UCI Health - Chao Family Comprehensive Cancer Center — Orange, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion criteria:
- Receiving a zanidatamab-containing therapy as part of a clinical trial or expanded access program
- Received zanidatamab prior to the approval date by the FDA for HER2+ la/m GEA
- Received the first infusion of zanidatamab prior to providing study consent
- For patients initiating chemotherapy backbone first, more than 2 months have elapsed before the first dose of zanidatamab
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (2 Sites)
- UCI Health - Chao Family Comprehensive Cancer Center — Orange, California
- University of Texas - MD Anderson Cancer Center Gastrointestinal Cancer Center — Houston, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.